This afternoon, our CMO Dimitry Nuyten will be presenting at KidneyCAN’s #KCRS24 Biotech Showcase where he’ll provide an overview of Arcus’s research in #kidneycancer, including our small molecule HIF-2α inhibitor. We look forward to an opportunity to discuss emerging therapeutics being developed for kidney cancer and collaborate with fellow clinical and translational researchers driving these advancements. Learn more about our science here: https://bit.ly/3S6i0tA
Arcus Biosciences’ Post
More Relevant Posts
-
Oncology | Immunology | Preclinical Research | Business & Corporate Development |
Great article to read for advantages and limitations of humanized mouse models for Immuno-oncology drug discovery.
Tap into the potential of humanized mouse models for immuno-oncology drug discovery. Immuno-oncology drug discovery is an exciting area of study that holds much potential in the fight against cancer. However, to unlock the full potential, there are important limitations to understand and challenges to overcome. This newly published article presents an overview of recent advances in humanized models relevant to immuno-oncology drug discovery. Advantages and limitations of such models, application of various humanized models for both efficacy and safety assessment, as well as opportunities for the future are discussed. Read the publication now: ➡️ https://bit.ly/3KBfJTq #Immunotherapy #HumanizedMice #MouseModels Rajendra Kumari Gerold Feuer Ludovic Bourre
-
-
We'll be participating in a fireside with John Newman, PhD, CFA at the Canaccord Genuity - Global Capital Markets 44th Annual Growth Conference in Boston later this month. More details, including how to listen to a webcast of the presentation are available in the PR below: https://lnkd.in/gAfketGX #CancerResearch #BreastCancer #PancreaticCancer #CGDriven #DrivenByYourSuccess #BreastCancerResearch #PancreaticCancerResearch #biotech #oncology #pelareorep #pela #immunotherapy
-
-
Summary of key XNK achievements in 2023 ▪️Approval of our manufacturing facility and tissue establishment. ▪️Delivery and presentation of preclinical data in our bladder cancer program. ▪️New pipeline project in liver cancer in collaboration with a global pharma. Even though the financial markets are challenging, we are really looking forward to 2024 and are convinced we will deliver great results! #nkcells #atmp #2023
-
Top Voice for R&D and Venture Investing: Imaging | Technology | Clinical Trials |
Immediate take-aways from #ASCO24: 🔥 AstraZeneca's Tagrisso, Imfinzi break new ground in #lungcancer and got standing ovation: https://lnkd.in/efcKJbTz 🏹 Emerging #ADC Drug Targets: https://lnkd.in/eXpjfdRP 🖥 Clinical data is becoming available from Artificial intelligence generated drugs. New data on matching drugs to patient profiles. Noting several #AI platforms: Massive Bio, BPGbio, Inc., Arsenal Biosciences, Inc. Giant steps towards curing cancer at #ASCO24! #Innovation #cancer #oncology #clinicalresearch #drugdevelopment
-
-
AdAlta and SYNthesis collaborate to form AdCella with a focus on cellular immunotherapies against cancer https://lnkd.in/eHpVWRxY
-
With the latest CAR applications, we can now more accurately target cancer cells with reduced side effects and improved outcomes. This #webinar discusses how Century Therapeutics, Inc accomplished this through development of a novel, dual-targeting CAR. https://okt.to/I52jpZ
Building Better CARs: Advancing Dual-Targeting Discovery
criver.com
-
Say goodbye to traditional, time-consuming, and complex drug combination screening methods. SynAI harnesses the power of compound SMILE sequences to swiftly pinpoint potential therapeutic combinations, resulting in substantial cost savings and a boost in research productivity. Explore our paper to understand the benefits SynAI can offer to your research. #AI #Cancer #DrugDiscovery #DrugScreening #CancerResearch #Biotech #Bioscience
Introducing SynAI: an AI-driven cancer drugs synergism prediction platform. Move beyond the time-intensive and cumbersome traditional methods of drug combination screening. SynAI leverages compound SMILE sequences to rapidly identify potential therapeutic combinations, significantly saving costs and enhancing research efficiency. Download our paper to discover the advantages SynAI brings to your research. ➡️ https://bit.ly/41YI0Le #AI #Cancer #DrugDiscovery #DrugScreening #CancerResearch #Biotech #Bioscience
Publication: SynAI: An AI-driven Cancer Drugs Synergism Prediction Platform
-
Roth Capital's latest Equity Research on Imugene Limited (ASX:IMU) highlights their continued positive outlook, maintaining a "Buy" rating with a 12-month price target of AUD $0.42. This valuation is based on robust clinical developments and strong financial health, notably their MAST trial for solid tumours. Key data from this trial support the potential of Imugene's innovative cancer treatments, positioning the company well for future growth. #Imugene #BiotechInvesting #CancerResearch #IMU #EquityResearch #smallcaps #smallcapstocks #cancer #biotech
-
-
Exciting news from Calculus portfolio company Oxford BioTherapeutics (OBT) - the first patient has been dosed with its lead candidate, OBT076, in a Phase 1b trial in adenoid cystic carcinomas (ACC) of the head and neck. OBT076 was discovered using OBT’s proprietary OGAP® platform, which is the world’s largest cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets. Click here to read more: https://lnkd.in/eNqHDa7W #immunotherapy #oncology #cancerresearch #biotech #eis #vct Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.
-
-
Effective antibody-drug conjugates (ADCs) hinge on understanding their intricate dynamics. This is where LC-MS/MS shines. Unlike Ligand Binding Assays (LBAs), LC-MS/MS offers unparalleled precision, capturing bound and unbound cytotoxins. Discover how this technique enables precise quantification of ADC components, driving the development of these life-saving therapies. Dive in and learn how we’re enhancing the future of cancer treatment! #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GdmST0
The Advantages of LC-MS/MS in Optimizing ADC Bioassays
